Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

HemoGenyx Pharmaceuticals Plc (5HU0) Stock Price & Analysis

0 Followers

5HU0 Stock Chart & Stats

€7.50€1.00(15.38%)
At close: 5:30 PM GMT+1
€5€10€15€20Feb 1Feb 1Mar 25Jan 22Sep 19Mar 24Oct 12
Day’s Range
EUR 7.50 - EUR 7.50
52-Week Range
EUR 4.64 - EUR 13.00
Previous Close
EUR 6.50
Volume
N/A
Average Volume (3M)
5
Market Cap
EUR 51.17M
Enterprise Value
EUR 45.81M
Total Cash (Recent Filing)
EUR 4.58M
Total Debt (Recent Filing)
EUR 1.85M
Price to Earnings (P/E)
―
Beta
-0.57
Next Earnings
Apr 23, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized Hematology And Stem-cell Focus

A focused pipeline in hematopoietic stem cells and hematology/oncology gives the company a defined scientific domain rather than a broad, undifferentiated research strategy. If its candidates demonstrate clinical value, this specialization could support differentiated intellectual property and partnership opportunities over time.

Debt Reduction

Reducing total debt provides some improvement in financial flexibility and may moderate financing pressure as development work continues. Although leverage remains material, the lower debt balance could reduce future repayment demands and make capital allocation more manageable than under the 2023 level.

Improved 2025 Cash-burn Rate

The reduction in operating cash outflow suggests some progress in controlling cash consumption, which is important for a pre-commercial biotechnology company. If sustained, lower burn could extend available funding and reduce the frequency or size of external capital requirements during development.

Bears Say

No Revenue Generation

A continuing absence of revenue leaves the business dependent on external funding while it advances its therapeutic programs. Without commercial sales, licensing income, or another established revenue stream, the company has limited internal capacity to finance research, absorb setbacks, or support operations.

Widening Net Losses

The sharp increase in net loss indicates that operating costs and development spending are not yet translating into financial progress. Persistent and widening losses can accelerate equity depletion, increase reliance on fundraising, and make the company more vulnerable if clinical or commercial milestones are delayed.

Leverage And Shrinking Equity Cushion

Debt exceeding equity leaves limited balance-sheet protection for a loss-making biotech and reduces flexibility to fund development internally. The substantial decline in equity means future losses could erode the remaining cushion further, increasing financing risk and potentially constraining strategic choices.

HemoGenyx Pharmaceuticals Plc News

5HU0 FAQ

What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest stock price was €4.64 and its highest was €13.00 in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is €51.17M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Sep 28, 2026. The company reported -€1.187 earnings per share for the quarter.
Is HemoGenyx Pharmaceuticals Plc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,896,786 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -€1.187 in its last earnings report. Following the earnings report the stock price went up 3.922%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in DE:5HU0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology